Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

H. Lundbeck A/S80 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of vortioxetine given as a single intravenous dose of 25 mg at initiation of an oral vortioxetine regimen of 10 mg/day for 7 days

The study consists of a 7-day double-blind Treatment Period (Day 0 to Day 6)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Major Depressive Disorder

Interventions

Vortioxetine infusion 25 mgDRUG

1 mg/mL, concentrate for solution for infusion, 25 mL (25 mg) administered in 250 mL saline over 2 hours as single dose for 7 days

Vortioxetine tablets 10 mg/dayDRUG

10 mg, tablets, oral administration once daily

Placebo infusionDRUG

concentrate for solution for infusion, 25 mL administered in 250 mL saline over 2 hours as single dose

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The patient has recurrent MDD, diagnosed according to DSM-5® and confirmed using the Mini-International Neuropsychiatric Interview (MINI). * The patient has a MADRS total score ≥ 30 at the Screening Visit. * As part of standard of care treatment, the patient is to be admitted to hospital due to the severity of the depressive symptoms and is willing to remain hospitalized for the duration of the study treatment period. * The patient has had the current MDE for ≥3 months but less than 12 months. * The patient has received treatment for the current episode with an SSRI/SNRI monotherapy (citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, sertraline) at an approved dose for at least 6 weeks. Exclusion criteria: -The patient has any current psychiatric disorder or Axis I disorder (DSM-5® criteria), established as the primary diagnosis, other than MDD, as assessed using the MINI or another diagnostic interview Other in- and exclusion criteria may apply

Locations (13)

Mental Health Centre 'Prof. Dr. Ivan Temkov', EOOD (BG1004)

Burgas, Bulgaria

SPH - Kardzhali, EOOD (BG1005)

Kardzhali, Bulgaria

MHAT "Dr. Hristo Stambolski", EOOD (BG1001)

Kazanlak, Bulgaria

Outcomes

Primary Outcomes

Change from baseline (Day 0) to Day 1 (24 h post-infusion) in MADRS-6 subscale score

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The primary endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.

Time frame: From baseline (Day 0) to Day 1 (24 h post-infusion)

Secondary Outcomes

Change from baseline (Day 0) to Day 3 in MADRS-6 subscale score

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.

Time frame: From baseline (Day 0) to Day 3

Change from baseline (Day 0) to Day 7 in MADRS-6 subscale score

The Montgomery and Åsberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Items in the scale assess apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts and suicidal thoughts. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60. The endpoint will be evaluated with MADRS-6 subscale score, calculated based on the scores on MADRS items 1, 2, 3, 7, 8, and 9 which cover core symptoms (apparent sadness, reported sadness, inner tension, lassitude, inability to feel, and pessimistic thoughts) and is more sensitive to the effect of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

oral administration once daily

State Psychiatric Hospital "Sv. Ivan Rilski" (BG1009)

Novi Iskar, Bulgaria

UMHAT 'Dr. Georgi Stranski', EAD (BG1006)

Pleven, Bulgaria

MHC - Ruse, EOOD (BG1007)

Rousse, Bulgaria

State Psychiatric Hospital (BG1008)

Tsarev Brod, Bulgaria

Mental Health Center-Vratsa EOOD (BG1002)

Vratsa, Bulgaria

Marienthali Kliinik (EE2001)

Tallinn, Estonia

Tartu University Hospital (EE2002)

Tartu, Estonia

...and 3 more locations

Time frame: From baseline (Day 0) to Day 7

Change in MADRS total score from baseline to Day 1, Day 3, Day 7

Time frame: From baseline to Day 1, Day 3, Day 7

≥50% decrease in MADRS total score from baseline on Day 1 and Day 3

Time frame: On Day 1 and Day 3

CGI-I score at Day 1, Day 3, Day 7

The Clinical Global Impression (CGI) provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I). The CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

Time frame: At Day 1, Day 3, Day 7

CGI-I response (defined as CGI-I score ≤2) on Day 1 and 3

Time frame: At Day 1 and 3

Change from baseline in CGI-S score to Day 1, Day 3, Day 7

The Clinical Global Impression (CGI) provides an overall clinician-determined summary measure that takes into account all available information, including knowledge of the patient's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the patient's ability to function. The CGI consists of two clinician-rated subscales: severity of illness (CGI-S) and global improvement (CGI-I). The CGI-S provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (Normal - not at all ill) to 7 (among the most extremely ill patients).

Time frame: From baseline to Day 1, Day 3, Day 7

CL/F of vortioxetine

Total plasma clearance of vortioxetine

Time frame: Day 0, Day 1, Day 7

Cav

average plasma concentration during a steady-state day

Time frame: Day 0, Day 1, Day 7